Abstract. Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) has been reported to have various functions in different cellular contexts. Our previous investigation discovered that IGFBP-rP1 inhibited retinal angiogenesis in vitro and in vivo by inhibiting the pro-angiogenic effect of VEGF and downregulating VEGF expression. Recently, IGFBP-rP1 was confirmed to be downregulated in the aqueous humor of patients with neovascular age-related macular degeneration compared with controls; however, its specific role remains unknown. The present study applied the technique of gene silencing, reverse transcription-quantitative PCR, western blotting, cell viability assays, cell motility assays and tube formation assays. Chemical hypoxic conditions and choroidal endothelial (RF/6a) cells were used to explore the effect of IGFBP-rP1-silencing on the phenotype activation of RF/6a cells under hypoxic conditions and to elucidate the underlying mechanisms. siRNA achieved IGFBP-rP1-silencing in RF/6A cells without cytotoxicity. IGFBP-rP1-silencing significantly restored the viability of RF/6a cells in hypoxia and enhanced hypoxia-induced migration and capillary-like tube formation of RF/6A cells. Furthermore, IGFBP-rP1-silencing significantly upregulated the expression of B-RAF, phosphorylated (p)-MEK, p-ERK and VEGF in RF/6A cells under hypoxic conditions; however, these upregulations were inhibited by exogenous IGFBP-rP1. These data indicated that silencing IGFBP-rP1 expression in RF/6A cells effectively promoted the hypoxia-induced angiogenic potential of choroidal endothelial cells by upregulating RAF/MEK/ERK signaling pathway activation and VEGF expression.

Introduction

Angiogenesis, a process of novel blood vessel formation from the pre-existing vasculature, serves a critical role in numerous human neovascularization diseases, such as diabetic retinopathy, ischemia/reperfusion injury and carcinogenesis (1). Vascular homeostasis is an intrinsically regulated procedure controlled by the balance of angiogenic and anti-angiogenic factors during normal physiological activities (1). Once homeostasis is interrupted, neovascularization is inevitable, becoming a major cause of irreversible vision loss in various clinical eye diseases, including retinopathy of prematurity, diabetic retinopathy and age-related macular degeneration (AMD) (2-4).

The underlying molecular mechanisms of choroidal neovascularization (CNV) are multifactorial and complicated. Previous studies have demonstrated that hypoxia and ischemia serve important roles in the formation of CNV (5-8). Multiple hypoxia-induced growth factors and inflammatory cytokines, including VEGF, hypoxia-inducible factor-1α, TNF-α and IL-1, stimulated the progression of CNV (5-8). Among these factors, VEGF is hypothesized to be the most important inducer of CNV under hypoxic conditions (5-9).

Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) is a soluble-secreted 36-kDa glycoprotein, also known as IGFBP7, mac25, TAF and angiomodulin (10,11). IGFBP-rP1 is distinct from other IGFBPs since it exhibits a low affinity for IGFs and a high affinity for insulin (10,11). Our previous studies have revealed that IGFBP-rP1 suppressed
the phenotype activation of retinal endothelial cells induced by VEGF in vitro and inhibited retinal angiogenesis by downregulating VEGF in vivo (12,13). Notably, IGFBP-rP1 was demonstrated to be decreased in the aqueous humor of patients with CNV secondary to AMD compared with control patients with cataract; however, its specific role remains unknown (14).

In the present study, IGFBP-rP1 specific small interfering RNA (siIGFBP-rP1) was transfected into choroidal endothelial (RF/6A) cells to block the expression of IGFBP-rP1 under hypoxic conditions to investigate the role of IGFBP-rP1-silencing in the hypoxia-induced angiogenic potential of choroidal endothelial cells and the underlying mechanisms.

Materials and methods

Media and reagents. Lipofectamine® 3000 transfection reagent was purchased from Thermo Fisher Scientific, Inc. PrimeScript reverse transcription (RT) reagent kit and SYBR Premix Ex Taq Real-Time PCR kit were purchased from Takara Bio, Inc. and were used in RT-quantitative (q)PCR assays. Recombinant human IGFBP-rP1 and goat anti-human IGFBP-rP1 polyclonal antibody (cat. no. AF1334) were obtained from R&D Systems, Inc. Rabbit anti-human GAPDH polyclonal (cat. no. 10494-1-AP) and mouse anti-human β-actin monoclonal (cat. no. 66009-1-lg) antibodies were obtained from ProteinTech Group, Inc. Rabbit anti-human VEGF polyclonal (cat. no. ab150766) antibodies were purchased from Abcam. The other primary antibodies, including rabbit anti-human B-RAF monoclonal (cat. no. 14814), rabbit anti-human phosphorylated-MEK (p-MEK) polyclonal (cat. no. 9121), rabbit anti-human MEK polyclonal (cat. no. 9122), rabbit anti-human phosphorylated-ERK (p-ERK) polyclonal (cat. no. 9101) and rabbit anti-human ERK polyclonal (cat. no. 9102) antibodies were purchased from Cell Signaling Technology, Inc. Horseradish peroxidase (HRP) mouse anti- goat (cat. no. sc2354), goat anti-rabbit (cat. no. sc-2004) and goat anti-mouse (cat. no. sc-2005) secondary antibodies were obtained from Santa Cruz Biotechnology, Inc. The PVDF membranes and Chemiluminescent HRP Substrate reagent were purchased from EMD Millipore. CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS Assay) was purchased from Promega Corporation. Transwell Permeable Supports with an 8-µm pore polycarbonate filter were purchased from Corning, Inc. Growth factor-reduced Matrigel matrix was purchased from BD Biosciences. All other chemicals were of reagent grade and obtained from Merck KGaA, unless otherwise specified.

Cell line and culture. RF/6A cells, a well-established choroid endothelial cell line for studying CNV pathogenesis (15-17), were obtained from the Cell Bank of the Chinese Academy of Sciences. The cells were cultured in RPMI-1640 medium (Thermo Fisher Scientific, Inc.) supplemented with 10% FBS (Thermo Fisher Scientific, Inc.) and 1% penicillin/streptomycin (GE Healthcare Life Sciences). The cells were maintained at 37°C in a 5% CO₂-humidified incubator and the medium was changed every 2 or 3 days. Prior to experimental intervention, the medium was replaced with serum-free RPMI-1640 for 12 h. Following siRNA transfection for 24 h, RF/6A cells were subjected to hypoxic conditions and IGFBP-rP1-restored conditions for further study. Cobalt chloride (CoCl₂; Merck KGaA) at a final concentration of 200 µmol/l or 1% O₂ in the presence of 5% CO₂ and 94% N₂ using a ProOx C21 System (BioSpherix, Ltd.) was used to mimic hypoxic conditions. To restore IGFBP-rP1 expression, recombiant human IGFBP-rP1 was added at a final concentration of 200 ng/ml for 24 h in the conditions of the siIGFBP-rP1 duplex 2 group, which has been demonstrated by previous studies (18-20). All experiments were performed in triplicate.

IGFBP-rP1 gene silencing. siRNAs for IGFBP-rP1 were purchased from Guangzhou RiboBio Co., Ltd. The sequences of the positive siIGFBP-rP1 duplex 1 and 2 were 5'-TCC-TCC-TCT-TCG-GAC-ACC-T-3' and 5'-GTC-GCT-ACA-TCG-GCT-GCT-C-3', respectively. RF/6A cells were seeded into six-well plates and transfected with 50 nM siRNA using Lipofectamine® 3000 transfection reagent. Briefly, 50 nM siRNA in Opti-MEM medium (Thermo Fisher Scientific, Inc.) was mixed with 4 µl Lipofectamine® 3000 and incubated for 25 min at room temperature prior to adding the mixture to the cells cultured in serum-free medium. The cells were incubated at 37°C for 5 h. Following this, the medium was replaced with RPMI-1640 complete medium for 48 h before the level of silencing was determined by RT-qPCR and western blotting. Scramble control siRNA, transfection reagent and blank control were used to compare the effects of siIGFBP-rP1.

RNA extraction and RT-qPCR. Total RNA was extracted from cultured RF/6A cells using a RNeasy Mini kit (Qiagen, Inc.), according to the manufacturer's protocol. Total RNA was eluted in 40 µl nuclease-free water. The concentration and purity of RNA were measured by spectrophotometry (NanoDrop 8000; Thermo Fisher Scientific, Inc.) at 15°C within 10 sec. In all RNA preparations, the ratio of optical density (OD)₂₆₀ to ₂₈₀ was 1.9:2.0. Equal amounts of RNA (0.5 µg) were converted into cDNA using PrimeScript RT reagent kit (Takara Bio, Inc.) and qPCR was performed using SYBR Premix Ex Taq real-time PCR kit (Takara Bio, Inc.), according to the manufacturer's protocols. The primers of IGFBP-rP1 and GAPDH were designed and synthesized by Sangon Biotech Co., Ltd. GAPDH served as an internal reference for the control. The primer sequences used were as follows: IGFBP-rP1 forward, 5'-AGC-TGT-GAG-GTC-ATC-GGA-AT-3' and reverse, 5'-GAC-AAG-CTT-CCC-GTT-CTC-AG-3'. The One-Step RT-PCR thermocycling conditions were as follows: 30 min of initial reverse transcription at 50°C, enzyme heat-activation at 95°C for 15 min, followed by 35 three-step amplification cycles of denaturation at 94°C for 40 sec, annealing at 60°C for 40 sec and extension at 72°C for 1 min. The qPCR thermocycling conditions were as follows: enzyme heat-activation at 95°C for 30 sec, followed by 40 two-step amplification cycles of denaturation at 95°C for 5 sec, annealing and extension at 60°C for 35 sec. Relative gene expression was calculated using a standard curve (the optical density was determined at 280 nm) and IGFBP-rP1 mRNA levels were normalized to GAPDH.
**Western blotting.** The RF/6A cells cultured in the IGFBP-rP1-silencing group, the hypoxic group and the control group were washed with phosphate-buffered saline (PBS) twice and lysed in ice-cold RIPA buffer (1 mmol/l phenylmethyl sulfonyl fluoride, 10 µg/ml leupeptin and 10 µg/ml aprotinin). Following 30 min on ice, lysates were scraped into microcentrifugation tubes and centrifuged at 14,000 x g for 10 min at 4°C. The supernatant was removed and the protein concentrations were quantified using a Pierce protein assay kit (Pierce; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. Cell lysates (30 µg protein/lane) were separated by 10% SDS-PAGE and transferred onto PVDF membranes. Following blocking with 5% blocking liquid diluted in Tris-buffered saline with 0.1% Tween-20 for 1 h at 37°C, membranes were incubated with different dilutions of primary antibodies overnight at 4°C. The following day, the membranes were washed three times and subsequently incubated with HRP-conjugated secondary antibodies for 1 h at room temperature. The primary antibodies used included IGFBP-rP1 (1:500), B-RAF (1:500), p-MEK (1:1,000), MEK (1:1,000), p-ERK (1:1,000), ERK (1:1,000), VEGF (1:1,000), GAPDH (1:1,000) and β-actin (1:1,000) antibodies. The dilution for the secondary antibodies was 1:5,000. Signals were detected by enhanced chemiluminescence (Western Lightning Plus-ECL; PerkinElmer, Inc.) and quantified by densitometry using Gel-Pro Analyzer software (version no. 4.0; Media Cybernetics, Inc.). GAPDH and β-actin were used as the internal controls.

**Cell viability assay.** Cell viability was evaluated by MTS colorimetric assays, as previously described (12). Briefly, cells were seeded in a 96-well plate (100 µl/well; 5x10^4 cells/ml) and allowed to attach overnight in the serum-free medium. Following this, cells were transfected with siRNA duplex 1 and 2 for 6, 12, 24, 48 and 72 h to plot growth curves. The cells transfected with siRNA duplex 2 for 24 h were then exposed to CoCl₂ mimetic and 1% O₂-induced hypoxia for 6, 12, 24, 48 and 72 h at 37°C in a 5% CO₂-humidified incubator to compare differences between these two types of hypoxic conditions on cell proliferation. Finally, MTS reagent (20 µl) was added to each well for 2 h and the absorbance and OD values at 490 nm were recorded using a Wallac Victor 1420 plate reader (PerkinElmer, Inc.).

**Cell motility assay.** Wound and Transwell assays were performed to assess cell motility. Confluent monolayers of the transfected or untransfected cells (4x10⁴ cells/well) in 6-multiwell plates were wounded using a pipette tip and washed with PBS three times. Following this, the plates were incubated in DMEM (1% FBS) containing 200 µmol/l CoCl₂ for 24 h at 37°C in a 5% CO₂ incubator. Images of the wounded area were captured under an inverted phase contrast microscope (IX50; Olympus Corporation) at a magnification of x200. The relative migration area of cells that had migrated from the edge of the wound was calculated using ImageJ software (version 1.50; National Institutes of Health).

The Transwell assays was performed as previously described (12). Briefly, the transfected or untransfected cells were placed in the upper chamber (6x10⁴ cells/chamber) at a final volume of 100 µl of the serum-free RPMI-1640 medium. Following this, the normal or CoCl₂-induced hypoxic medium was placed in the bottom chamber at a final volume of 600 µl. Following incubation for 24 h, the filters were fixed in 10% paraformaldehyde for 20 min at room temperature and stained with hematoxylin for 15 min at room temperature. Cells on the lower surface of the filters were counted in five randomly selected fields/filter under a light microscope (BX50; Olympus Corporation) at a magnification of x200.

**Tube formation assay.** Tube formation assays were performed by placing ice-cold growth factor-reduced Matrigel matrix in a prechilled 96-well plate (50 µl/well), followed by incubation at 37°C for 30 min to allow polymerization. Next, siIGFBP-rP1 transfected cells (8x10⁴ cells/well) were seeded on the Matrigel-coated 96-well plate and incubated for 24 h under normal or hypoxic conditions. Enclosed capillary-like tube structures within the Matrigel layer from five randomly selected fields/well were captured under an inverted phase contrast microscope (BX40; Olympus Corporation) at a magnification of x50. The tube length was measured by Image-Pro Plus Analyzer software (version no. 6.0; Media Cybernetics, Inc.).

**Statistical analysis.** A one-way ANOVA followed by Dunnett's post-hoc test was used to evaluate differences between the control and intervention groups assessed by different experiments. All tests were performed using SPSS for Windows (version no. 13.0; SPSS Inc.). Data are presented as the mean ± standard deviation. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**IGFBP-rP1-silencing in RF/6A cells by siRNA does not exhibit cytotoxicity.** Two different siRNA sequences were designed for transfection to attain a higher knockdown efficiency. Firstly, the expression of IGFBP-rP1 was confirmed in RF/6A cells without the specific siRNA transfection. Following this, the effectiveness of siIGFBP-rP1 transfection was measured by RT-qPCR and western blotting. IGFBP-rP1 expression exhibited a significant decrease in siIGFBP-rP1 duplex 1- and 2-transfected cells at the mRNA and protein levels (P<0.05 vs. the blank control group; Fig. 1). By contrast, there were no significant differences between the cells cultured in the blank control, transfection reagent and scramble control siRNA groups (P>0.05).

Moreover, the cell growth curve demonstrated that siIGFBP-rP1 duplex 1 and 2 significantly promoted RF/6A cell proliferation at 12, 24 and 48 h compared with the blank control group (P<0.01; Fig. 2). No significant differences in cell viability were observed among the groups at 6 and 72 h (P>0.05). Furthermore, the siIGFBP-rP1 duplex 2 demonstrated a stronger pro-proliferative effect compared with the siIGFBP-rP1 duplex 1 at 24 h (P<0.01). Since the siIGFBP-rP1 duplex 2 exhibited a higher inhibition efficiency and no cytotoxicity, it was selected for the following experiments.

**IGFBP-rP1-silencing restores RF/6A cell viability under hypoxia.** As revealed in Fig. 3, the OD values of RF/6A cells detected by MTS colorimetric assay decreased significantly

**Molecular Medicine Reports 22: 4837-4847, 2020**
IGFBP-rP1 silencing stimulates hypoxia-induced migration and tube formation of RF/6A cells. In order to determine the effect of IGFBP-rP1 silencing on phenotype activation of RF/6A cells under CoCl₂-induced hypoxic conditions, chemotactic motility and tube formation assays were performed on siIGFBP-rP1 transfected and untransfected cells under normal and hypoxic conditions. The scramble control siRNA-transfected cells were used as control cells.

The relative migration area of cells that had migrated from the edge of the wound and those that had migrated across the filter toward the lower surface due to hypoxia were ~2.5x and ~2x that of the control, respectively (Fig. 4). siIGFBP-rP1 transfection significantly increased cell mobility compared with non-transfected cells, under both normoxic (P<0.01 vs. the hypoxia group) and hypoxic conditions (P<0.01 vs. the siIGFBP-rP1 group).

As presented in Fig. 5, extensive and enclosed networks of capillary-like tubes were observed in the siIGFBP-rP1 and hypoxia + siIGFBP-rP1 groups, while incomplete and sparse tube networks formed by the untransfected cells under normal conditions. Tube formation, as determined by the total tube length, increased ~7-fold (the siIGFBP-rP1 group vs. the control group) or ~5-fold (the hypoxia + siIGFBP-rP1 group vs. the hypoxic group) following siIGFBP-rP1 transfection, as compared with non-transfection under normal or hypoxic conditions, respectively. Furthermore, tube length was significantly increased in the hypoxia group compared with the control group (P<0.01).

IGFBP-rP1-silencing enhances hypoxia-induced RAF/MEK/ERK signaling pathway activation in RF/6A cells. To understand the underlying mechanisms of restored cell viability, enhanced migration and tube formation by siIGFBP-rP1-transfected cells in hypoxic conditions, RF/6A cells cultured in normal conditions and CoCl₂-induced hypoxic conditions with or without siIGFBP-rP1 transfection and exogenous human IGFBP-rP1 were detected to determine the changes of key molecules in the RAF/MEK/ERK signaling pathway using western blotting. As revealed in Fig. 6, under hypoxic conditions, the expression of B-RAF, p-MEK, and p-ERK were significantly increased compared with that under normal conditions.
transfection significantly decreased (P<0.01). No significant differences were observed among the groups at 6 and 72 h. OD values are presented as the mean ± standard deviation of 4 wells/group and experiments were performed in triplicate. IGFBP-rP1, insulin-like growth factor binding protein-related protein 1; siIGFBP-rP1, IGFBP-rP1 specific siRNA; OD, optical density.

(P<0.05). In addition, following IGFBP-rP1-silencing, the phosphorylation level of the RAF/MEK/ERK signaling pathway was significantly increased, both under normal (the siIGFBP-rP1 group vs. the control group, P<0.05) and hypoxic conditions (the hypoxia + siIGFBP-rP1 group vs. the hypoxia group, P<0.05). Furthermore, with the addition of exogenous human IGFBP-rP1, the upregulation of B-RAF, p-MEK and p-ERK induced by siIGFBP-rP1 transfection significantly decreased (P<0.01). No significant differences in the expression of MEK and ERK were observed between the six groups (data not shown).

**IGFBP-rP1-silencing upregulates the hypoxia-induced VEGF expression in RF/6A cells.** Since VEGF expression may be involved in the process of choroidal angiogenesis mediated by IGFBP-rP1 (12), western blotting was performed to detect the distinct protein expression of VEGF under different intervention conditions. As presented in Fig. 6, the expression of VEGF increased ~4- or ~7 fold in the hypoxia group and siIGFBP-rP1 group, respectively, compared with control. When the transfected cells were cultured in hypoxic conditions, the expression of VEGF significantly increased (~8-fold), compared with control. Additionally, the upregulation of VEGF in siIGFBP-rP1-transfected cells under hypoxic conditions was markedly increased compared with transfected cells under normal conditions (P<0.01; data not shown). Similar to the RAF/MEK/ERK pathway, exogenous human IGFBP-rP1 significantly downregulated the expression of VEGF in siIGFBP-rP1-transfected cells, under both normoxic and hypoxic conditions (P<0.01).

**Discussion**

The number of patients with AMD, a common age-associated eye disease, is increasing worldwide due to exponential population ageing. The projected number of individuals with AMD for 2020 is 196 million, with an expected increase to 288 million in 2040 (21,22). Since 2010, AMD has become the 3rd most common cause of blindness and the 4th leading cause of visual impairment worldwide (23). IGFs, the family of important proteins that regulate various cellular processes, including proliferation, differentiation, apoptosis and neovascularization, may be involved in molecular mechanisms that contribute to the pathogenesis of AMD, involving oxidative stress, mitochondrial dysfunction and impaired resistance to molecular stressors in the choriocapillaris (24-30). The members of the IGF family, including IGFFBP-2, IGFFBP-6 and IGFFBP-rP1, were demonstrated to be increased in patients with exudative AMD (31). However, further research reported that IGFFBP-rP1 was decreased in patients with neovascular AMD (14). This difference in IGFFBP-rP1 expression highlighted the possibility of IGFFBP-rP1 being an endogenous factor regulating AMD progression.

The IGFBP-rP1 gene is located on chromosome 4q and encodes a 256-amino acid protein (10,11). IGFBP-rP1 is distinct from other IGFFBs, as it can highly bind to insulin yet lowly to IGFs and IGFBP-rP1 has been demonstrated to...
Figure 4. Cell motility of siIGFBP-rP1-transfected or untransfected cells cultured under normoxic or hypoxic conditions for 24 h is detected by wound and Transwell assays. (A) Representative images showing that RF/6A cells migrated across the wound boundary to the blank area (light microscopy; magnification, x400) and (B) passed across the filter toward the lower surface (light microscopy; magnification, x200). Hypoxia significantly promoted cell mobility compared with the controls (*P<0.01). siIGFBP-rP1 transfection (siIGFBP-rP1 group) further enhanced cell migration, as compared with untransfected cells cultured in hypoxic conditions (hypoxia group; **P<0.01). The transfected cells cultured in hypoxic conditions (hypoxia + siRNA group) exhibited a significantly increased migration ability compared with the transfected cells cultured in normoxic conditions (siIGFBP-rP1 group; **P<0.01). Values are presented as the mean ± standard deviation of 4 samples/group and experiments were performed in triplicate and are quantified as the ratio relative to the control group. IGFBP-rP1, insulin-like growth factor binding protein-related protein 1; siIGFBP-rP1, IGFBP-rP1 specific siRNA.

Figure 5. IGFBP-rP1-silencing stimulates hypoxia-induced tube formation of RF/6A cells. Representative images (inverted phase contrast microscopy; magnification, x50) demonstrating that RF/6A cells formed capillary-like tube structures within the Matrigel layer in different mediums. RF/6A cells in hypoxic conditions or siIGFBP-rP1-transfected cells significantly formed completely enclosed capillary-like tubes compared with the controls (*P<0.01 the hypoxia group vs. the control group; **P<0.01 the siIGFBP-rP1 group vs. the control group). Moreover, siIGFBP-rP1 transfection further promoted tube formation in RF/6A cells in the hypoxia + siIGFBP-rP1 group compared with the siIGFBP-rP1 group (**P<0.01). The values are presented as the mean ± standard deviation of 4 samples/group and experiments were performed in triplicate and are quantified as the ratio relative to the control group. IGFBP-rP1, insulin-like growth factor binding protein-related protein 1; siIGFBP-rP1, IGFBP-rP1 specific small interfering RNA.
have various functions in different cellular contexts (10,11). IGFBP-rP1 was described to have both tumor suppressing and enhancing properties in regard to cell proliferation (32). Additionally, IGFBP-rP1 was associated with the senescence and apoptosis of different cell lines, including human breast cancer cell lines and prostate cancer cell lines (33,34). Previous studies revealed a stimulatory effect of IGFBP-rP1 in the adhesion, migration and proliferation of acute myeloid leukemia (35,36). Accumulating evidence has indicated that IGFBP-rP1 downregulation may participate in tumorigenesis, acting as a cancer suppressive factor in various types of cancer, including breast, colorectal, prostate and hepatocellular cancer (37-40). Our previous study revealed that IGFBP-rP1 inhibited the stimulatory effect of VEGF on retinal angiogenesis in vitro (12). It was also revealed that IGFBP-rP1 inhibited ocular neovascularization by downregulating VEGF expression in a mouse model of O₂-induced retinopathy (13). Furthermore, IGFBP-rP1 was confirmed to be downregulated in the aqueous humor of patients with wet AMD; however, the downregulation of IGFBP-rP1 in the pathogenesis of wet AMD remains unknown (14). In order to examine the effects of IGFBP-rP1 on the biological behavior of choroidal endothelial cells under a pathological state, gene silencing was performed to interfere with the expression of IGFBP-rP1 in choroidal endothelial cells and hypoxic conditions were used to mimic the internal conditions.
environment in patients with AMD. RF/6A cells, a rhesus choroid endothelial cell line widely used in research to simulate ophthalmic micro-endothelial cells and explore the influences of external factors and corresponding mechanisms (15-17,41,42) were used to observe the influence of IGFBP-rP1-silencing and hypoxia on CNV formation in vitro. RNA interference, which allows for the silencing of mammalian genes with great specificity and potency, has been extensively used in several fields to investigate gene functions and design novel therapeutic methods (43-48).

Using this technique, IGFBP-rP1-silencing was successfully accomplished in RF/6A cells. Cell growth curves confirmed that siIGFBP-rP1 duplex 1 and 2 both significantly promoted RF/6A cell proliferation at 12, 24 and 48 h, and siIGFBP-rP1 duplex 2 demonstrated a more significant effect compared with duplex 1 at 24 h. Furthermore, no significant differences were observed between the transfected cells and untransfected cells at 6 and 72 h. These results suggested that there was no significant impairment in cell viability following the silencing of IGFBP-rP1 expression at 6-72 h.

Hypoxia is considered to serve an important role in CNV formation, a critical characteristic of wet AMD and the main cause of visual impairment in patients with subsequent bleeding or fibrosis (6-8,49-51). CoCl2-induced chemical hypoxia, a reliable method of mimicking hypoxia (52-55), was used to imitate the internal environment during choroidal angiogenesis. Since CoCl2 can unexpectedly and markedly decrease pyruvate dehydrogenase phosphorylation and lead to an enhanced glycolytic poise in mammalian cells (56), the different effects between CoCl2, mimetic and 1 % O2-induced hypoxia on cell proliferation were compared. Both hypoxic conditions significantly decreased cell proliferation and IGFBP-rP1-silencing restored cell viability in these hypoxic conditions. The difference on cell proliferation was not obvious between these two types of hypoxic environment under the current experimental conditions, thus the present study continued to use CoCl2 mimetic hypoxia in subsequent experiments. The results demonstrated that hypoxic conditions significantly enhanced migration and capillary-like tube formation in RF/6A cells. These results indicated that abnormal environments, including hypoxia, serve an important role in the development of CNV formation, which was consistent with previous studies (54,55,57).

The present study further explored the role of IGFBP-rP1-silencing in the angiogenic potential of RF/6A cells under hypoxic conditions. The results demonstrated that the transfected cells under hypoxia were significantly activated to migrate from the edge of the wound, pass across the filter toward the lower surface and form extensive and enclosed networks of capillary-like tubes compared with controls. The migrated area and number of siIGFBP-rP1 transfected cells in hypoxic conditions, as well as total tube length, were significantly higher compared with siIGFBP-rP1 transfected cells in normal conditions. These results indicated that the downregulation of IGFBP-rP1 significantly promoted vascular branching and sprouting under hypoxia, which implied that IGFBP-rP1 may act as an anti-angiogenic regulator of choroidal angiogenesis. During the process of AMD-related choroidal vascular homeostasis deterioration and neovascularization, the downregulation of anti-angiogenic factors has been demonstrated to be a common pathological manifestation (58-61). This may explain why the concentration of IGFBP-rP1 in the aqueous humor of patients with wet AMD was significantly lower compared with controls (14). Along with excessively synthesized and released VEGF in the hypoxic eyes of these patients (9,62), the balance was further disrupted by the downregulation of IGFBP-rP1, which may significantly accelerate the occurrence and development of CNV.

The RAF/MEK/ERK signaling pathway serves a critical role in regulating cell division, proliferation, senescence and apoptosis during physiological and pathological processes, such as adipocyte physiology, insulin signaling, oxidative stress and cancer progression (63-66). Excessive activation of the key molecules of this signaling pathway in the majority of types of cancer results in an unbalanced cell proliferation and apoptosis inhibition or escapement (67,68). Additionally, it has been confirmed that the activation of the RAF/MEK/ERK signaling pathway modulated the role of VEGF in tumor pathogenesis and metastasis (69-72). The present study demonstrated that the RAF/MEK/ERK signaling pathway was significantly activated when choroidal endothelial cells cultured under hypoxic conditions were transfected with siIGFBP-rP1, while exogenous IGFBP-rP1 downregulated the activation level of this pathway. IGFBP-rP1 may promote the pro-angiogenic effect of VEGF, particularly in pathological conditions, including hypoxia, which was reported by the present results. Furthermore, the results of the present study revealed that the hypoxia-induced VEGF expression was significantly upregulated in RF/6A cells by blocking IGFBP-rP1 expression. The regulation of VEGF expression demonstrated the same trend as the activation of the RAF/MEK/ERK signaling pathway. Additionally, previous studies have indicated that the RAF/MEK/ERK signaling pathway regulated VEGF expression in diabetic animals (73,74) and hypoxic conditions (75,76). These results suggested that IGFBP-rP1 may regulate VEGF expression in choroidal endothelial cells through the RAF/MEK/ERK signaling pathway under hypoxia. In combination, the inhibition of IGFBP-rP1 further activated the RAF/MEK/ERK signaling pathway and upregulated VEGF expression, which may concurrently participate in choroidal endothelial cell phenotype activation, CNV formation and AMD progression under hypoxia. Since patients with partial wet AMD have a poor or no response to anti-VEGF treatment, novel drugs that can resolve this problem are urgently required. IGFBP-rP1 may become a therapeutic target in choroidal angiogenesis due to its potential inhibition of ophthalmic neovascularization.

The present study had limitations. Although there was no significant difference in cell viability between CoCl2, mimetic and 1 % O2-induced hypoxia, certain effects induced by CoCl2 may differ from those of actual hypoxia. Therefore, the role of IGFBP-rP1 in RF/6A cells under physical hypoxia requires further investigation. Furthermore, despite the extensive application of RF/6A cells as the closest choroidal endothelial cell line to human species in studies on choroidal angiogenesis in vitro, the signaling circuitry has been altered in this immortalized cell line. Therefore, the exact effect of IGFBP-rP1 on choroidal angiogenesis and the RAF/MEK/ERK signaling pathway needs to be further explored in human choroidal endothelial cells and in an in vivo model.

In conclusion, the present study revealed that IGFBP-rP1-silencing promoted cell proliferation and stimulated...
hypoxia-induced migration and tube formation of RF/6A cells. Additionally, the results confirmed that IGFBP-rP1-silencing effectively promoted hypoxia-induced angiogenic potential of choroidal endothelial cells by upregulating VEGF expression, probably by activating the RAF/MEK/ERK signaling pathway. Further research should be conducted to determine whether IGFBP-rP1 acts as an angiogenesis inhibitor in vivo and its effect on other ocular tissues; the real-world application of IGFBP-rP1 or an associated drug in clinical practice requires further research in future studies.

Acknowledgements

Not applicable.

Funding

The present study was supported by grants from the National Nature Science Foundation for Young Scholars of China (grant no. 81200701), the National Key R&D Program of China (grant nos. 2016YFC0904800 and 2019YFC0840607), the National Science and Technology Major Project of China (grant no. 2017ZX09304010) and the Bethune-Lumitin Research Funding for Young or Middle-aged Ophthalmologists (grant no. BJ-LM2019001J).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

SZ and HW conducted the siRNA assays, the restoration assays, data acquisition and were major contributors in drafting the original manuscript. MM and ZZha performed the cell viability assays, cell motility assays, tube formation assays, created graphs and were major contributors in drafting the original manuscript. ZZhe and HW performed the signaling pathway assays, analysis and interpretation of data and made major contributions in editing the original manuscript. XX and TS made substantial contributions to conception and design, and made critical revising of the original manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Yancopoulous GD, Davis S, Gale NW, Rudge JS, Wiegand SJ and Holash J: Vascular-specific growth factors and blood vessel formation. Nature 407: 242-248, 2000.
2. Daven V, Eldem BM, Talks JS, Korobelnik JF, Mitchell P, Finger RP, Sakamoto T, Wong TY, Evuherheo O, Carter G and Carrasco J: Real-world data in retinal diseases treated with anti-vascular endothelial growth factor (anti-VEGF) therapy-a systematic approach to identify and characterize data sources. BMC Ophthalmol 19: 206, 2019.
3. Campbell M and Doyle SL: Current perspectives on established and novel therapies for pathological neovascularization in retinal disease. Biochem Pharmacol 164: 321-325, 2019.
4. Campochiaro PA: Molecular pathogenesis of retinal and choroidal vascular diseases. Prog Retin Eye Res 49: 67-81, 2015.
5. Wang H, Chai Z, Hu D, Ji Q, Xin J, Zhang C and Zhong J: A global analysis of CNVs in diverse yak populations using whole-genome resequencing. BMC Genomics 20: 61, 2019.
6. Park SM, Lee K, Huh M, Eom S, Park B, Kim KH, Park DH, Kim DS and Kim HK: Development of an in vitro 3D choroidal neovascularization model using chemically induced hypoxia through an ultra-thin, free-standing nanofiber membrane. Mater Sci Eng C Mater Biol Appl 104: 109964, 2020.
7. Alivand MR, Sabouni F and Soheili ZS: Probable chemical hypoxia effects on progress of CNV through induction of promoter CpG demethylation and overexpression of IL17RC in human RPE cells. Curr Eye Res 41: 1245-1254, 2016.
8. Andre H, Tunik S, Aronsson M and Kvanta A: Hypoxia-inducible factor-1α is associated with sprouting angiogenesis in the murine laser-induced choroidal neovascularization model. Invest Ophthalmol Vis Sci 56: 6591-6604, 2015.
9. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW and Hartnett ME: Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 27: 331-371, 2008.
10. Hwa V, Oh Y and Rosenfeld RG: The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 20: 761-787, 1999.
11. Forbes BE, McCarthy P and Norton RS: Insulin-like growth factor binding proteins: A structural perspective. Front Endocrinol (Lausanne) 3: 38, 2012.
12. Sun T, Cao H, Xu L, Zhu B, Gu Q and Xu X: Insulin-like growth factor binding protein-related protein 1 mediates VEGF-induced proliferation, migration and tube formation of retinal endothelial cells. Curr Eye Res 36: 341-349, 2011.
13. Zhang P, Wang H, Cao H, Xu X and Sun T: Insulin-like growth factor-binding protein-related protein 1 inhibit retinal neovascularization in the mouse model of oxygen-induced retinopathy. J Ocul Pharmacol Ther 33: 459-465, 2017.
14. Sung HJ, Han Ji, Lee JW, Uhm KB and Heo K: TCCR/WSX-1 is a novel angiogenic factor in age-related macular degeneration. Mol Vis 18: 234-240, 2012.
15. Zhu M, Liu X, Wang S, Miao J, Wu L, Yang X, Wang Y, Kang L, Li W, Cui C, et al: PKR promotes choroidal neovascularization via upregulating the PI3K/Akt signaling pathway in VEGF expression. Mol Vis 22: 1361-1374, 2016.
16. Feng Y, Wang J, Yuan Y, Zhang X, Shen M and Yuan F: miR-539-5p inhibits experimental choroidal neovascularization by targeting CXCR7. Faseb J 32: 1626-1639, 2018.
17. Chan C, Hsiao C, Li H, Fang J, Chang D and Hung C: The inhibitory effects of gold nanoparticles on VEGF-A-induced cell migration in choroid-retina endothelial cells. Int J Mol Sci 21: 109, 2019.
18. Liu Z, Liu H, Fang W, Yang Y, Wang H and Peng J: Insulin-like growth factor binding protein 7 modulates estrogen-induced trophoblast proliferation and invasion in HTR-8 and JEG-3 cells. Cell Biochem Biophys 63: 73-84, 2012.
19. Tamura K, Yoshie M, Hashimoto T and Seki K: Hypoxia effect of insulin-like growth factor-binding protein-7 (IGFBP7) on in vitro angiogenesis of vascular endothelial cells in the rat corona luteum. J Reprod Dev 60: 447-453, 2014.  
20. Verhagen HMJ, van Gils N, Martaäe T, van Rhenen A, Rutten A, Denkers F, de Leeuw DC, Smit MA, Tsui M, de Vos Klootwijk LL, et al: IGFBP7 induces differentiation and loss of survival of human acute myeloid leukemia stem cells without affecting normal hematopoiesis. Cell Rep 25: 3021-3035, 2018.
21. Rozen MP, Durhuus JA, Krogh NM, Subhi Y, Kirkwood TB, Westendorp RG and Sørensen TL: Age-related macular degeneration: A two-level model hypothesis. Prog Retin Eye Res 100825: 2019.
24. Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY and Wong TY: Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. Lancet Glob Health 2: e106-e116, 2014.

25. Lamberto NG, ElShelmani H, Singh MK, Mansergh FC, Lambert NG, ElShelmani H, Singh MK, Mansergh FC, Pan H and Finkel T: Key proteins and pathways that regulate angiogenesis: From cancer to cardiovascular disease. Cytokine 2015.

26. Pan H and Finkel T: Key proteins and pathways that regulate lifespan. J Biol Chem 292: 6452-6460, 2017.

27. Jesko H, Stephei A, Lukiw WJ and Strosznajder RP: The cross-talk between sphingolipids and insulin-like growth factor signaling: Significance for aging and neurodegeneration. Mol Neurobiol 56: 3501-3521, 2019.

28. Haywood NJ, Slater TA, Matthews CJ and Wheatcroft SB: The insulin like growth factor and binding protein family: Novel therapeutic targets in obesity & diabetes. Mol Metab 19: 86-96, 2019.

29. Slater T, Haywood NJ, Matthews C, Cheema H and Wheatcroft SB: Insulin-like growth factor binding proteins and angiogenesis: From cancer to cardiovascular disease. Cytokine Growth Factor Rev 46: 28-35, 2019.

30. Bach LA: Endothelial cells and the IGF system. J Mol Endocrinol 54: R1-R13, 2015.

31. Cha DM, Boo SJ, Kim HJ, Lee C and Park KH: Comparative analysis of angiogenic human cytokine levels between patients with exudative age-related macular degeneration and normal controls. Invest Ophthalmol Vis Sci 54: 7038-7044, 2013.

32. Zhu S, Xu F, Zhang J, Ruan W and Lai M: Insulin-like growth factor binding protein-related protein 1 and cancer. Clin Chim Acta 431: 23-32, 2014.

33. Wang HM, Bin Guan RS, Poot M, Quinn LS and Swishchelm K: Insulin-like growth factor binding protein-related protein 1 inhibits proliferation of MCF-7 breast cancer cells via a senescence-like mechanism. Cell Growth Differ 13: 205-213, 2002.

34. Matutughi K, Yasumoto H, Mita K, Matsubara A, Shima H, Igarashi M, Tamura K and Usui T: Restoration of insulin-like growth factor binding protein-related protein 1 has a tumor-suppressive activity through induction of apoptosis in human prostate cancer. Cancer Res 63: 7717-7723, 2003.

35. Hu S, Chen R, Man X, Feng X, Cen J, Gu W, He H, Li J, Chai Y and Chen Z: Function and expression of insulin-like growth factor-binding protein 7 (IGFBP-7) gene in childhood acute myeloid leukemia. Pediatr Hematol Oncol 28: 279-287, 2011.

36. Laranjeira AB, de Vasconcellos JF, Sodek L, Spago MC, Fornaznicin MC, Tone LG, Brandalise SR, Novill AE and Yunes JA: IGFBP7 participates in the reciprocal interaction between acute lymphoblastic leukemia and BM stromal cells and in leukemia resistance to asparaginase. Leukemia 26: 1001-1011, 2012.

37. Burger AM, Leyland-Jones B, Banerjee K, Spyroulous DD and Seth AK: Essential roles of IGFBP-3 and IGFBP-p1 in breast cancer. Eur J Cancer 41: 1515-1527, 2005.

38. Zhu S, Zhang J, Xu F, Xu E, Ruan W, Ma Y, Huang Q and Lai M: IGFBP-p1 suppresses epithelial-mesenchymal transition and metastasis in colorectal cancer. Cell Death Dis 6: e1095, 2015.

39. Seki M, Teishima J, Mochizuki H, Mutaguchi K, Yasumoto H, Oka K, Nagamatsu H, Shoji K and Matsubara A: Restoration of IGFBP-p1 increases radiosensitivity and chemosensitivity in hormone-refractory human prostate cancer. Hiroshima J Med Sci 62: 13-19, 2013.

40. Akerman M, Guro C, Li X, Rajasekaran D, Mendoza RG, Robertson CL, Jariwala N, Yuan F, Subler MA, Windle J et al: IGFBP7 deletion promotes hepatocellular carcinoma. Cancer Res 77: 4014-4025, 2017.

41. Jiang H, Wu M, Liu Y, Song L, Li S, Wang X, Zhang YF, Fang J and Wu S: Serine racemase deficiency attenuates choroidal neovascularization and reduces nitric oxide and VEGF levels by retinal pigment epithelial cells. J Neurochem 143: 375-388, 2017.

42. Chen S, Zhou Y, Zhou L, Guan Y, Zhang Y and Han X: Anti-angiogenic effects of DMBT in age-related macular degeneration by inhibition of VEGF secretion through ROS-dependent signaling pathway. Mol Cell Biochem 448: 225-235, 2018.

43. Milhavet O, Gary DS and Mattsson MP: RNA interference in biology and medicine. Pharmacol Rev 55: 629-648, 2003.

44. Corydon TJ: Antiangiogenic eye gene therapy. Hum Gene Ther 16: 525-537, 2005.

45. Moore NA, Bracha P, Hussain RM, Morral N and Ciulla TA: Gene therapy for age-related macular degeneration. Expert Opin Biol Ther 17: 1235-1244, 2017.

46. Moore SM, Skowronska-Krawczyk D and Chao DL: Emerging concepts for RNA therapeutics for inherited retinal disease. Adv Exp Med Biol 1185: 85-89, 2019.

47. Yang XM, Wang YS, Zhang J, Li Y, Xu JF, Zhu J, Zhao W, Chu DK and Wiedemann P: Role of PI3K/Akt and MEK/ERK in mediating hypoxia-induced expression of HIF-1alpha and VEGF in laser-induced rat choroidal neovascularization. Invest Ophthalmol Vis Sci 56: 1873-1879, 2009.

48. Lee CS, Choi EY, Lee SC, Koh HJ, Lee JE and Chung JH: Resveratrol inhibits hypoxia-induced vascular endothelial growth factor expression and pathological neovascularization. Ophthalmology 130: 56-43, 2013.

49. Jin J, Yuan F, Shen MQ, Feng YF and He QL: Vascular endothelial growth factor regulates primate choroid-retinal endothelial cell proliferation and tube formation through PI3K/Akt and MEK/ERK dependent signaling. Mol Cell Biochem 381: 267-272, 2013.

50. Li R, Du J and Chang Y: Role of autophagy in hypoxia-induced angiogenesis of RF/6A cells in vitro. Curr Eye Res 41: 1566-1570, 2016.

51. Cui K, Zhang S, Liu X, Yang Z, Huan J, Song A: Inhibition of TBK1 reduces choroidal neovascularization in vitro and in vivo. Biochem Biophys Res Commun 503: 202-208, 2018.

52. Borcar A, Menze MA, Toner M and Hand SC: Metabolic preconditioning of mammalian cells: Mimetic agents for hypoxia lack fidelity in promoting phosphorylation of pyruvate dehydrogenase. Cell Tissue Res 351: 99-106, 2013.

53. Cabral T, Mello L, Lima LH, Polido J, Regatiere CV, Belfort RJ and Sheibani N: Negative regulators of angiogenesis: Important targets for treatment of exudative AMD. J Ophthalmic Vis Res 13: 470-486, 2018.

54. Farnoodian M, Wang S, Dietz J, Nickells RW, Sorenson CM and Sheibani N: Negative regulators of angiogenesis: Important targets for treatment of exudative AMD. Clin Sci (Lond) 131: 1763-1780, 2017.

55. Farnoodian M, Sorenson CM and Sheibani N: Negative regulators of angiogenesis: Important targets for treatment of exudative AMD. J Ophthalmic Vis Res 13: 470-486, 2018.
64. Sun Y, Liu W, Liu T, Feng X, Yang N and Zhou H: Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. J Recept Signal Transduct Res 35: 600-604, 2015.

65. Rezatabar S, Karimian A, Rameshkina V, Parsian H, Majidinia M, Kopp TA, Bishayee A, Sadeghina A, Yousefi M, Monirialamdari M and Yousefi B: RAS/MAPK signaling functions in oxidative stress, DNA damage response and cancer progression. J Cell Physiol 234: 14951-14965, 2019.

66. Marampon F, Ciccarelli C and Zani BM: Biological rationale for targeting MEK/ERK pathways in anti-cancer therapy and to potentiate tumour responses to radiation. Int J Mol Sci 20: 2530, 2019.

67. Khaliq M and Fallahi-Sichani M: Epigenetic mechanisms of escape from BRAF oncogene dependency. Cancers (Basel) 11: 1480, 2019.

68. Degirmenci U, Wang M and Hu J: Targeting aberrant RAS/RAF/MEK/ERK signaling for cancer therapy. Cells 9: 198, 2020.

69. Huang M, Huang B, Li G and Zeng S: Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2/RAF/MEK/ERK and PI3K/AKT pathways in cholangiocarcinoma cell. BMC Gastroenterol 18: 169, 2018.

70. Yamana S, Tokiyama A, Fujita H, Terao Y, Horibe S, Sasaki N, Satomi-Kobayashi S, Hirata KI and Rikitake Y: Necl-4 enhances the PLCγ-c-Raf-MEK-ERK pathway without affecting internalization of VEGFR2. Biochem Biophys Res Commun 490: 169-175, 2017.

71. Gong J, Zhou S and Yang S: Vanillic acid suppresses HIF-1α expression via inhibition of mTOR/p70S6K/4E-BP1 and Raf/MEK/ERK pathways in human colon cancer HCT116 cells. Int J Mol Sci 20: e465, 2019.

72. Pachmayr E, Treese C and Stein U: Underlying mechanisms for distant metastasis-molecular biology. Visc Med 33: 11-20, 2017.

73. Zhang EY, Gao B, Shi HL, Huang LF, Yang L, Wu XJ and Wang ZT: 20(S)-protopanaxadiol enhances angiogenesis via HIF-1α-mediated VEGF secretion by activating p70S6 kinase and benefits wound healing in genetically diabetic mice. Exp Mol Med 49: e387, 2017.

74. Ye X, Xu G, Chang Q, Fan J, Sun Z, Qin Y and Jiang AC: ERK1/2 signaling pathways involved in VEGF release in diabetic rat retina. Invest Ophthalmol Vis Sci 51: 5226-5233, 2010.

75. Hou SY, Li YP, Wang JH, Yang SL, Wang Y, Wang Y and Kuang Y: Aquaporin-3 inhibition reduces the growth of NSCLC cells induced by hypoxia. Cell Physiol Biochem 38: 129-140, 2016.

76. Shen K, Ji L, Gong C, Ma Y, Yang L, Fan Y, Hou M and Wang Z: Notoginsenoside P1 promotes angiogenesis via HIF-1α-mediated VEGF secretion and the regulation of PI3K/AKT and Raf/MEK/ERK signaling pathways. Biochem Pharmacol 84: 784-792, 2012.